Sanjeev Arora

Summary

Affiliation: University of New Mexico
Country: USA

Publications

  1. ncbi Project ECHO: linking university specialists with rural and prison-based clinicians to improve care for people with chronic hepatitis C in New Mexico
    Sanjeev Arora
    University of New Mexico School of Medicine, Albuquerque, NM 87131 0001, USA
    Public Health Rep 122:74-7. 2007
  2. ncbi Expanding access to hepatitis C virus treatment--Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care
    Sanjeev Arora
    University of New Mexico Health Sciences Center, Project ECHO, Albuquerque, NM, USA
    Hepatology 52:1124-33. 2010
  3. ncbi Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life
    Sanjeev Arora
    Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131 0001, USA
    J Gastroenterol Hepatol 21:406-12. 2006
  4. ncbi Academic health center management of chronic diseases through knowledge networks: Project ECHO
    Sanjeev Arora
    Department of Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131 0001, USA
    Acad Med 82:154-60. 2007
  5. ncbi Outcomes of treatment for hepatitis C virus infection by primary care providers
    Sanjeev Arora
    Department of Internal Medicine, University of New Mexico, Albuquerque, USA
    N Engl J Med 364:2199-207. 2011
  6. ncbi Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites
    Stanley Yu
    Department of Gastroenterology, University of New Mexico, Albuquerque, New Mexico 87131 0001, USA
    Am J Gastroenterol 104:1686-92. 2009
  7. ncbi Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study
    Robert G Gish
    Department of Medicine, Division of Hepatology and Complex GI, Physicians Foundation, California Pacific Medical Center, San Francisco, CA, USA
    J Hepatol 47:51-9. 2007
  8. ncbi Taribavirin in the treatment of hepatitis C
    Paulina Deming
    University of New Mexico Health Sciences Center, College of Pharmacy, MSC 09 5360, 1 University of New Mexico, Albuquerque, NM 87131 0001, USA
    Expert Opin Investig Drugs 20:1435-43. 2011
  9. ncbi Partnering urban academic medical centers and rural primary care clinicians to provide complex chronic disease care
    Sanjeev Arora
    Project ECHO, University of New Mexico School of Medicine, Albuquerque, Sanjeev Arora, USA
    Health Aff (Millwood) 30:1176-84. 2011
  10. ncbi The shocking cost of turnover in health care
    J Deane Waldman
    Health Sciences Center, Anderson Schools of Management, University of New Mexico, Albuquerque, NM, USA
    Health Care Manage Rev 29:2-7. 2004

Research Grants

  1. Project ECHO Extension for Community Healthcare Outcomes
    Sanjeev Arora; Fiscal Year: 2006
  2. Expansion of Rural Health Care Research Infrastructure through the ECHO Model
    Sanjeev Arora; Fiscal Year: 2007

Detail Information

Publications15

  1. ncbi Project ECHO: linking university specialists with rural and prison-based clinicians to improve care for people with chronic hepatitis C in New Mexico
    Sanjeev Arora
    University of New Mexico School of Medicine, Albuquerque, NM 87131 0001, USA
    Public Health Rep 122:74-7. 2007
    ..Project ECHO has increased access to state-of-the art hepatitis C virus care for patients living in rural areas or prisons. Because of its success with hepatitis C, this project is being expanded to other chronic medical conditions...
  2. ncbi Expanding access to hepatitis C virus treatment--Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care
    Sanjeev Arora
    University of New Mexico Health Sciences Center, Project ECHO, Albuquerque, NM, USA
    Hepatology 52:1124-33. 2010
    ....
  3. ncbi Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life
    Sanjeev Arora
    Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131 0001, USA
    J Gastroenterol Hepatol 21:406-12. 2006
    ..HRQoL in the present population was also compared with HRQoL in patients with elevated ALT levels, observed in a previous study...
  4. ncbi Academic health center management of chronic diseases through knowledge networks: Project ECHO
    Sanjeev Arora
    Department of Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131 0001, USA
    Acad Med 82:154-60. 2007
    ....
  5. ncbi Outcomes of treatment for hepatitis C virus infection by primary care providers
    Sanjeev Arora
    Department of Internal Medicine, University of New Mexico, Albuquerque, USA
    N Engl J Med 364:2199-207. 2011
    ..With the use of video-conferencing technology, the ECHO program trains primary care providers to treat complex diseases...
  6. ncbi Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites
    Stanley Yu
    Department of Gastroenterology, University of New Mexico, Albuquerque, New Mexico 87131 0001, USA
    Am J Gastroenterol 104:1686-92. 2009
    ..The aim of this study was to compare the treatment responses of Hispanics and non-Hispanic whites (NHW) treated with pegylated interferon and ribavirin for chronic HCV...
  7. ncbi Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study
    Robert G Gish
    Department of Medicine, Division of Hepatology and Complex GI, Physicians Foundation, California Pacific Medical Center, San Francisco, CA, USA
    J Hepatol 47:51-9. 2007
    ..Taribavirin, a ribavirin prodrug, has shown a lower incidence of anemia. We sought to determine the efficacy and safety of taribavirin vs. ribavirin combined with pegylated interferon in patients with chronic hepatitis C (CHC)...
  8. ncbi Taribavirin in the treatment of hepatitis C
    Paulina Deming
    University of New Mexico Health Sciences Center, College of Pharmacy, MSC 09 5360, 1 University of New Mexico, Albuquerque, NM 87131 0001, USA
    Expert Opin Investig Drugs 20:1435-43. 2011
    ..The dosing strategy of taribavirin favors concentration within the liver to reduce treatment-limiting rates of anemia but may be insufficient to prevent virologic relapse...
  9. ncbi Partnering urban academic medical centers and rural primary care clinicians to provide complex chronic disease care
    Sanjeev Arora
    Project ECHO, University of New Mexico School of Medicine, Albuquerque, Sanjeev Arora, USA
    Health Aff (Millwood) 30:1176-84. 2011
    ..As of March 2011, 298 Project ECHO teams across New Mexico have collaborated on more than 10,000 specialty care consultations for hepatitis C and other chronic diseases...
  10. ncbi The shocking cost of turnover in health care
    J Deane Waldman
    Health Sciences Center, Anderson Schools of Management, University of New Mexico, Albuquerque, NM, USA
    Health Care Manage Rev 29:2-7. 2004
    ..Here, turnover includes hiring, training, and productivity loss costs. Minimum cost of turnover represented a loss of >5 percent of the total annual operating budget...
  11. ncbi Chronic hepatitis C in pregnancy
    Eliza M F Berkley
    Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA
    Obstet Gynecol 112:304-10. 2008
    ..To estimate outcomes, to determine whether appropriate follow-up was performed for pregnant patients with hepatitis C virus (HCV), and to show that maternal and neonatal complications would be higher in the HCV-positive group...
  12. ncbi Ethical issues in the treatment of hepatitis C
    Cynthia M A Geppert
    New Mexico Veterans Affairs Healthcare System, and Department of Psychiatry, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131-0001, USA
    Clin Gastroenterol Hepatol 3:937-44. 2005
    ....
  13. ncbi Randomized evaluation of a web based interview process for urology resident selection
    Satyan K Shah
    Division of Urology, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131, USA
    J Urol 187:1380-4. 2012
    ..We determined whether a web based interview process for resident selection could effectively replace the traditional on-site interview...
  14. ncbi Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy
    Mark Sulkowski
    Viral Hepatitis Center, Johns Hopkins Medical Institutions, 1830 E Monument St, Room 448, Baltimore, MD 21205, USA
    Clin Pharmacol Ther 77:214-24. 2005
    ..Our objective was to quantify the pharmacokinetics of methadone and the pharmacokinetics and pharmacodynamics of peginterferon alfa-2a (40 kd) in patients with chronic hepatitis C undergoing methadone maintenance therapy...
  15. ncbi Widening the door: the evolution of hepatitis C treatment in patients with psychiatric disorders
    Cynthia M A Geppert
    Hepatology 46:957-9. 2007

Research Grants2

  1. Project ECHO Extension for Community Healthcare Outcomes
    Sanjeev Arora; Fiscal Year: 2006
    ....
  2. Expansion of Rural Health Care Research Infrastructure through the ECHO Model
    Sanjeev Arora; Fiscal Year: 2007
    ..Research Arm on Diabetes, PI Kathleen Colleran, MD Research Arm on Pediatric Overweight, PI Keri Bolton Oetzel, PhD, MPH, LPC Research Arm on Buprenorphine, PI Miriam Komaromy, MD Research Arm on Medical Ethics, PI Anne Simpson, MD, CMD ..